Stoke Therapeutics, Inc. STOK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Global Development Activity | $19.89M+13.7% | $17.49M— | —— | —— | —— | |
| IP License | $0-100% | $150.78M— | —— | —— | —— | |
| Operating Expenses by Product | ||||||
| ADOA | -$6.81M-10.7% | -$6.16M-5.2% | -$5.85M-3.0% | -$5.68M+17.5% | -$6.89M+7.0% | |
| MECP2 | $184K+397% | $37K+118% | -$209K+59.5% | -$516K+46.8% | -$970K+8.9% | |
| Other External Program Costs | -$10.19M-15.3% | -$8.84M+0.1% | -$8.84M-5.9% | -$8.35M+2.5% | -$8.56M+2.4% | |
| Other Non Program Costs Research And Development | -$6.42M-4.4% | -$6.15M-11.0% | -$5.54M-2.3% | -$5.42M-2.7% | -$5.27M+1.0% | |
| Payroll And Other Personnel Costs Research And Development | -$56.81M-9.9% | -$51.71M-13.1% | -$45.71M-6.9% | -$42.76M-6.1% | -$40.3M-7.6% | |
| SYNGAP1 | -$3.74M-12.1% | -$3.33M-34.8% | -$2.47M-26.5% | -$1.96M-42.0% | -$1.38M-4.4% | |
| Zorevunersen | -$74.01M-3.0% | -$71.83M-23.1% | -$58.34M-29.7% | -$44.96M-10.0% | -$40.89M-27.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stoke Therapeutics, Inc. break its business down?
- Stoke Therapeutics, Inc. (STOK) reports revenue by product across 4 parts — Global Development Activity, IP License, License and Service. Each is extracted from the segment footnotes and tracked over time.
- Where does Stoke Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stoke Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.